PDCD1 and neoplasm: While we showed that a single dose of 60 kBq [225Ac]Ac-FAPI-46 was inefficacious in the FSA tumor model, we tested RLT efficacy also in the FSA-Fmed tumor bearing mice using 60 kBq [225Ac]Ac-FAPI-46, with or without PD-1 ICB (Fig. 6A).